The state of Michigan currently has 2 active clinical trials seeking participants for Primary Biliary Cholangitis research studies. These trials are conducted in various cities, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo.
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
Recruiting
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: University of Michigan Health System, Ann Arbor, Michigan +1 locations
Conditions: Primary Biliary Cholangitis (PBC)
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Recruiting
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Henry Ford Medical Center - Columbus, Detroit, Michigan
Conditions: Primary Biliary Cholangitis